1-5 of 5
Andreas Peter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Subphenotype-Dependent Benefits of Bariatric Surgery for Individuals at Risk for Type 2 Diabetes

Free
Leontine Sandforth, Violeta Raverdy, Arvid Sandforth, Pierre Bauvin, Estelle Chatelain, Helene Verkindt, Geltrude Mingrone, Caterina Guidone, Ornella Verrastro, Karin Zhou, Rami Archid, André Mihaljevic, Robert Caiazzo, Gregory Baud, Camille Marciniak, Mikael Chetboun, Marlene Ganslmeier, Vitória Minelli Faiao, Martin Heni, Louise Fritsche, Anja Moller, Konstantinos Kantartzis, Andreas Peter, Rainer Lehmann, Robert Wagner, Katsiaryna Prystupa, Andreas Fritsche, Norbert Stefan, Hubert Preissl, Andreas L. Birkenfeld, Reiner Jumpertz von Schwartzenberg, François Pattou
Journal: Diabetes Care
Diabetes Care 2025;48(6):996–1006
https://doi.org/10.2337/dc25-0160
Published: 11 April 2025
View article titled, Subphenotype-Dependent Benefits of Bariatric Surgery for Individuals at Risk for Type 2 Diabetes
Open the PDF for Subphenotype-Dependent Benefits of Bariatric Surgery for Individuals at Risk for Type 2 Diabetes in another window
Journal Articles

Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Free
Stephanie Kullmann, Julia Hummel, Robert Wagner, Corinna Dannecker, Andreas Vosseler, Louise Fritsche, Ralf Veit, Konstantinos Kantartzis, Jürgen Machann, Andreas L. Birkenfeld, Norbert Stefan, Hans-Ulrich Häring, Andreas Peter, Hubert Preissl, Andreas Fritsche, Martin Heni
Journal: Diabetes Care
Diabetes Care 2022;45(2):398–406
https://doi.org/10.2337/dc21-1136
Published: 29 October 2021
View article titled, Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Open the PDF for Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial in another window
Journal Articles

Increased Hepatic ACE2 Expression in NAFL and Diabetes—A Risk for COVID-19 Patients?

Free
Jelena Soldo, Martin Heni, Alfred Königsrainer, Hans-Ulrich Häring, Andreas L. Birkenfeld, Andreas Peter
Journal: Diabetes Care
Diabetes Care 2020;43(10):e134–e136
https://doi.org/10.2337/dc20-1458
Published: 11 September 2020
View article titled, Increased Hepatic ACE2 Expression in NAFL and Diabetes—A Risk for COVID-19 Patients?
Open the PDF for Increased Hepatic ACE2 Expression in NAFL and Diabetes—A Risk for COVID-19 Patients? in another window
Journal Articles

Comment on Hedderson et al. Prepregnancy SHBG Concentrations and Risk for Subsequently Developing Gestational Diabetes Mellitus. Diabetes Care 2014;37:1296–1303

Open Access
Norbert Stefan, Andreas Peter, Hans-Ulrich Häring
Journal: Diabetes Care
Diabetes Care 2014;37(12):e278–e279
https://doi.org/10.2337/dc14-1272
Published: 08 November 2014
View article titled, Comment on Hedderson et al. Prepregnancy SHBG Concentrations and Risk for Subsequently Developing Gestational Diabetes Mellitus. Diabetes Care 2014;37:1296–1303
Open the PDF for Comment on Hedderson et al. Prepregnancy SHBG Concentrations and Risk for Subsequently Developing Gestational Diabetes Mellitus. Diabetes Care 2014;37:1296–1303 in another window
Journal Articles

Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver

Open Access
Rainer Lehmann, PHD, Holger Franken, PHD, Sascha Dammeier, PHD, Lars Rosenbaum, PHD, Konstantinos Kantartzis, MD, Andreas Peter, MD, Andreas Zell, PHD, Patrick Adam, MD, Jia Li, PHD, Guowang Xu, PHD, Alfred Königsrainer, MD, Jürgen Machann, PHD, Fritz Schick, MD, Martin Hrabé de Angelis, PHD, Matthias Schwab, MD, Harald Staiger, PHD, Erwin Schleicher, PHD, Amalia Gastaldelli, PHD, Andreas Fritsche, MD, Hans-Ulrich Häring, MD, Norbert Stefan, MD
Journal: Diabetes Care
Diabetes Care 2013;36(8):2331–2338
https://doi.org/10.2337/dc12-1760
Published: 11 July 2013
View article titled, Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver
Open the PDF for Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver in another window
Includes: Supplementary data